Jonathan Kapke, DO Internal Medicine - Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: N16w24131 Riverwood Dr, Waukesha, WI 53188 Phone: 262-696-5690 |
Dr. Derek Steven Serna, M.D. Internal Medicine - Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: N16w24131 Riverwood Dr, Waukesha, WI 53188 Phone: 262-696-5690 |
Federico A. Sanchez, M.D. Internal Medicine - Hematology & Oncology Medicare: Medicare Enrolled Practice Location: N14w23833 Stone Ridge Dr, Suite 200, Waukesha, WI 53188 Phone: 262-513-2033 |
Peter Haan Johnson, M.D. Internal Medicine - Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 721 American Ave Ste 108, Prohealth Care Regional Cancer Center, Waukesha, WI 53188 Phone: 262-928-5350 |
Dr. Christopher R Hake, MD Internal Medicine - Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 725 American Ave, Phc Regional Cancer Center, Waukesha, WI 53188 Phone: 262-928-2570 |
Dr. Laura Lynn Raftery, M.D. Internal Medicine - Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 721 American Ave Ste 108, Prohealth Care Regional Cancer Center, Waukesha, WI 53188 Phone: 262-928-2570 |
News Archive
Researchers from Massachusetts Eye and Ear have, for the first time, identified rapidly proliferating cells (known as "neural crest-derived progenitor cells") in the corneal endothelium of specimens from normal corneas and from corneas with Fuchs' Endothelial Corneal Dystrophy (FECD), a condition in which the cells responsible for keeping the cornea clear die prematurely — often leading to blindness.
Pfizer and PA Consulting Group have announced the signing of a transaction in which Pfizer will purchase the remaining 90% ownership of Meridica Limited
Lipid nanoparticles (SLNs and NLCs) are regarded as highly promising systems for delivering nucleic acids in gene therapy.
Also, the Washington Post fact-checks another ad which positions Sen. Lamar Alexander, R-Tenn., as a key Obamacare opponent and claims the health law increased insurance premiums 50 percent.
Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced the publication of a research article in Bioorganic & Medicinal Chemistry [18:7966-7974, 2010] on the anticancer activity of quinoxalinyl-piperazine compounds.
› Verified 1 days ago